Analyst Reco. Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-06-05 pm EDT			5-day change	1st Jan Change
232.77 ^USD	+2.02%		+3.30%	+12.48%

Jun. 05	J&J beats lawsuit alleging that talc caused three women's cancer	RE
Jun. 04	CereVasc Raises $85 Million in Funding Led by Piper Sandler Merchant Banking	MT

Analyst Reco.

May. 13	Leerink Partners Upgrades Johnson & Johnson to Outperform From Market Perform, Adjusts PT to $265 From $252	MT
Apr. 20	Guggenheim Adjusts Price Target on Johnson & Johnson to $266 From $244, Maintains Buy Rating	MT
Apr. 16	Daiwa Securities Adjusts PT on Johnson & Johnson to $246 From $237, Maintains Outperform Rating	MT
Apr. 16	Argus Research Adjusts PT on Johnson & Johnson to $275 From $240, Maintains Buy Rating	MT
Apr. 15	Argus Raises Price Target on Johnson & Johnson to $275 From $240	MT
Apr. 15	BofA Securities Raises Price Target on Johnson & Johnson to $254 From $253, Maintains Neutral Rating	MT
Apr. 15	Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says	MT
Apr. 15	BofA Securities Raises Price Target on Johnson & Johnson to $254 From $253, Maintains Neutral Rating	MT
Apr. 15	Johnson & Johnson Q1 Reinforces Growth Outlook on New Product Cycle, Morgan Stanley Says	MT
Apr. 15	Johnson & Johnson Highlights Pipeline Catalysts, Reaffirms Growth Outlook After Q1 Beat, RBC Says	MT
Apr. 15	RBC Raises Price Target on Johnson & Johnson to $265 From $255, Keeps Outperform Rating	MT
Apr. 15	Morgan Stanley Lifts Price Target on Johnson & Johnson to $283 From $267, Maintains Overweight Rating	MT
Apr. 15	Stifel Adjusts Price Target on Johnson & Johnson to $250 From $220, Maintains Hold Rating	MT
Apr. 15	Barclays Adjusts Price Target on Johnson & Johnson to $255 From $234, Maintains Equalweight Rating	MT
Apr. 15	Goldman Sachs Adjusts Price Target on Johnson & Johnson to $275 From $265, Maintains Buy Rating	MT
Apr. 15	Wells Fargo Adjusts Price Target on Johnson & Johnson to $263 From $240, Maintains Overweight Rating	MT
Apr. 15	Bernstein Adjusts Price Target on Johnson & Johnson to $251 From $225, Maintains Market Perform Rating	MT
Apr. 15	JPMorgan Adjusts Price Target on Johnson & Johnson to $260 From $250, Maintains Neutral Rating	MT
Apr. 15	Leerink Partners Adjusts PT on Johnson & Johnson to $252 From $232, Maintains Market Perform Rating	MT
Apr. 15	Raymond James Adjusts PT on Johnson & Johnson to $258 From $237, Maintains Outperform Rating	MT
Apr. 07	Citigroup Adjusts Price Target on Johnson & Johnson to $285 From $274, Maintains Buy Rating	MT
Apr. 07	Guggenheim Adjusts Price Target on Johnson & Johnson to $244 From $240, Maintains Buy Rating	MT
Mar. 30	Johnson & Johnson's Vision Segment Targets Up to High-Single Digit Long-Term Growth, RBC Says	MT
Mar. 19	Barclays Adjusts Price Target on Johnson & Johnson to $234 From $217, Maintains Equalweight Rating	MT
Mar. 17	HSBC Adjusts Price Target on Johnson & Johnson to $280 From $265, Maintains Buy Rating	MT